Skip to main content

Table 2 NNRTI mutations and treatment information for three individual patients in SGA

From: The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy

ART duration

Patient ID

Viral load

CD4 count

K103N

G190A

Y181C

K101E

SGA quantity

20.5

HENDRC593

500

498

6 (35.3)

11 (64.7)

6 (35.3)

11 (64.7)

17

27.5

500

691

8 (42.1)

11 (57.9)

8 (42.1)

11 (57.9)

19

38.9

2976

770

4 (26.7)

11 (73.3)

7 (46.7)

11 (73.3)

15

44.8

91000

655

3 (15.8)

16 (84.2)

5 (26.3)

16 (84.2)

19

49.9

120000

595

0 (0.0)

23 (100.0)

2 (8.7)

23 (100.0)

23

61.5

52000

696

0 (0.0)

16 (94.1)

5 (29.4)

16 (94.1)

17

76.1

170000

551

0 (0.0)

20 (100.0)

9 (45.0)

18 (90.0)

20

23.9

ANHDRC0106

44730

222

10 (100.0)

1 (10.0)

10 (100.0)

0 (0.0)

10

30.1

159000

196

5 (41.7)

3 (25.0)

12 (100.0)

7 (58.3)

12

35.5

94700

255

5 (33.3)

3 (20.0)

15 (100.0)

10 (66.7)

15

42.6

379000

153

3 (21.4)

3 (21.4)

14 (100.0)

11 (78.6)

14

46.4

17600

294

0 (0.0)

11 (84.6)

13 (100.0)

13 (100.0)

13

52.6

33100

256

1 (7.1)

10 (71.4)

14 (100.0)

13 (92.9)

14

20.5

HENDRC622

2076000

104

10 (83.3)

10 (83.3)

0 (0.0)

2 (16.7)

12

27.4

7263

164

14 (93.3)

15 (100.0)

0 (0.0)

1 (6.7)

15

33.0

17160

142

12 (75.0)

16 (100.0)

0 (0.0)

4 (25.0)

16

44.7

13160

138

9 (81.8)

11 (100.0)

0 (0.0)

2 (18.2)

11

49.9

66000

176

9 (90.0)

10 (100.0)

1 (10.0)

1 (10.0)

10

56.8

81000

130

4 (22.2)

18 (100.0)

2 (11.1)

5 (27.8)

18

61.5

39000

181

8 (42.1)

19 (100.0)

6 (31.6)

1 (5.3)

19